NeuroOne Medical Technologies (NMTC) Stock Price, News & Analysis

Company Overview

NeuroOne Medical Technologies is a medical device company focused on advancing neural interface technologies for diagnostic and therapeutic applications. The company’s proprietary NeuroOne Ultracompliant Solution (NUS®) platform features a flexible polymer microelectrode array designed to conform to delicate neural tissue. By combining high-fidelity recording and precise stimulation capabilities, NeuroOne aims to improve outcomes for patients suffering from chronic pain, movement disorders and other neurological conditions.

At the core of NeuroOne’s product pipeline is the MicroLead® neural interface, a next-generation device engineered to enhance the safety and efficacy of spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). The MicroLead’s ultrathin, biocompatible design minimizes tissue trauma while enabling higher resolution mapping of neural signals. The company is also developing complementary implantation and delivery systems to streamline surgical procedures and support broader clinical adoption.

Since its inception in 2015, NeuroOne has built a portfolio of patents covering its polymer electrode technology, system architectures and manufacturing processes. The company is headquartered in Cleveland, Ohio, with manufacturing facilities in Costa Rica, and collaborates with leading academic medical centers across North America and Europe. Through clinical trials and research partnerships, NeuroOne seeks to validate its platform’s potential in diverse therapeutic areas, including neuromodulation for epilepsy, Parkinson’s disease and refractory pain syndromes.

NeuroOne’s leadership team combines deep expertise in neurosurgery, biomedical engineering and medical device commercialization. Under the guidance of President and Chief Executive Officer David Backes, the company has expanded its R&D footprint and secured key regulatory designations. With an experienced board of directors and a growing pipeline of proprietary assets, NeuroOne Medical Technologies is positioned to play a pivotal role in the evolution of next-generation neural interfaces.

Key Stats

• Today's Range: $0.73 to $0.86
• 50-Day Range: $0.56 to $0.85
• 52-Week Range: $0.40 to $1.39
• Volume: 453,702 shs
• Average Volume: 191,068 shs
• Market Capitalization: $42.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.45
• Consensus Rating: Buy

NeuroOne Medical Technologies Stock Analysis - MarketRank™

NeuroOne Medical Technologies scored higher than 53% of companies evaluated by MarketBeat, and ranked 533rd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NeuroOne Medical Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NeuroOne Medical Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroOne Medical Technologies is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroOne Medical Technologies is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroOne Medical Technologies has a P/B Ratio of 28.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of NeuroOne Medical Technologies has been sold short.

Short Interest Ratio / Days to Cover

NeuroOne Medical Technologies has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroOne Medical Technologies has recently decreased by 44.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroOne Medical Technologies does not currently pay a dividend.

Dividend Growth

NeuroOne Medical Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.23% of the float of NeuroOne Medical Technologies has been sold short.

Short Interest Ratio / Days to Cover

NeuroOne Medical Technologies has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroOne Medical Technologies has recently decreased by 44.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

NeuroOne Medical Technologies has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for NeuroOne Medical Technologies this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added NeuroOne Medical Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NeuroOne Medical Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,569.00 in company stock.

Percentage Held by Insiders

Only 8.90% of the stock of NeuroOne Medical Technologies is held by insiders.

Percentage Held by Institutions

Only 16.07% of the stock of NeuroOne Medical Technologies is held by institutions.

NMTC Stock Analysis - Frequently Asked Questions

How have NMTC shares performed this year?

NeuroOne Medical Technologies' stock was trading at $0.8259 at the beginning of 2025. Since then, NMTC stock has increased by 2.9% and is now trading at $0.85.

How were NeuroOne Medical Technologies' earnings last quarter?

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. The business earned $1.39 billion during the quarter, compared to analyst estimates of $1.27 billion. NeuroOne Medical Technologies had a negative net margin of 75.41% and a negative trailing twelve-month return on equity of 334.64%.
Read the conference call transcript.

How do I buy shares of NeuroOne Medical Technologies?

Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroOne Medical Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroOne Medical Technologies investors own include Schwab US Large-Cap ETF (SCHX), NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Ford Motor (F), Meta Platforms (META) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NMTC
• CIK: 1500198
• Web: www.originalsourcemusic.com
• Phone: (952) 426-1383
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NeuroOne Medical Technologies: $1.45
• High Price Target: $1.45
• Low Price Target: $1.45
• Potential Upside/Downside: +70.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.32 million
• Net Margins: -75.41%
• Pretax Margin: -75.40%
• Return on Equity: -334.64%
• Return on Assets: -124.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.13
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: $3.45 million
• Price / Sales: 12.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 28.44

Miscellaneous

• Outstanding Shares: 49,820,000
• Free Float: 45,384,000
• Market Cap: $42.50 million
• Optionable: Optionable
• Beta: 0.66